

### ***Pharmaceutical Anti-Corruption Compliance Conference in Philadelphia Dec. 11-12***

The pharmaceutical; medical device and medical supply industry have all been hit hard by Foreign Corrupt Practices Act (FCPA) enforcement actions. Just this summer, enforcement actions were announced against Pfizer which contained several obligations, beyond the 13 point minimum *best practices* compliance program, that were included in its 'Enhanced Compliance Obligations'. What are some of the specific issues that make FCPA compliance in these industries so challenging? More importantly what are some of the responses and techniques that compliance professionals can recommend that their companies implement to help protect it from, and mitigate, FCPA compliance risk? If you want to explore these questions, and others, and help get some answers I hope that you can attend next week's Pharmaceutical Anti-Corruption Compliance Conference in Philadelphia, hosted by Hanson Wade. Rarely has there been an event so targeted to answering the compliance challenges to several related industries.

Initially, I would note that there is a wealth of compliance talent that will speak at the event. Including, but not limited to: Gary Giampetruzzi, Vice President & Assistant General Counsel, Pfizer; Luran S. D'Alessio, Vice President US Market Business Practices & Compliance, Merck & Company; Susan Barsky, Associate Director, Global Compliance, Teva Pharmaceuticals; Adriana Mosailov, Director of Corporate Compliance & Business Practices, Senior Compliance Officer, Endo Pharmaceuticals; Justin A. Dillon, Vice President, Chief Ethics & Compliance Officer, Ipsen Biopharmaceuticals; Edward Stueck, Senior Director of Monitoring and Assurance, AstraZeneca; Una Nash, Associate Director, Compliance and Ethics, Transparency and Disclosure, Boehringer Ingelheim Pharmaceuticals Inc.; Justin A. Dillon, Vice President, Chief Ethics & Compliance Officer, Ipsen Biopharmaceuticals; Adriana Mosailov, Director of Corporate Compliance & Business Practices, Senior Compliance Officer, Endo Pharmaceuticals; and Jim Dawson, Vice President, Chief Compliance Officer, United Therapeutics Corporation.

There will also be a bevy of top-notch compliance practitioners from outside industries and entities which will add a rich assortment to the speakers and panelists. These include Jeffery Spalding, Assistant General Counsel, Halliburton; Lynee H. Campos, Compliance Counsel, GE Aviation; Virginia Gibson, Partner, Hogan Lovells US LLP; Richard C. Smith, Partner, Fulbright & Jaworski LLP and Jay Mumford, Vice President, Ethisphere Institute.

Mike Koehler, the FCPA Professor, will lead an exploration of the implications of the FCPA's "New Era" and how to make sure your compliance program will stand up to new, stricter enforcement. You will come to understand how global anti-corruption laws and regulations interplay with the FCPA and find out what steps are being taken to harmonize this language and how you can factor in global regulations. You will hear from compliance practitioners who have been through FCPA investigations and find out how they overhauled their compliance programs to prevent reoccurrence. Compliance professionals outside the pharmaceutical industry can pick up valuable cross-sector lessons from high risk industries. There will be a presentation on

internal audit and using the audit process to mitigate risk. I will be speaking on understanding how to deal with tag-along FCPA civil litigation.

If you are on the East Coast, in the pharmaceutical, medical device, medical supply industry or other, and want to attend one of the top FCPA related events for compliance practitioners and hear from some of the top in-house compliance talent in this arena, then this is the one for you. But there is one other reason to attend. The FCPA Professor will be the second speaker on the first day of the event. I am sure he will have some thoughts on the recently released FCPA Guidance and this will be your first opportunity to hear the Professor share some of his opinions on the Guidance. That alone will be worth the price of admission. Also I am Chairing the first day of the event and I know I will have some questions for the Professor on the Guidance. I hope that you can join us next week.

For more details and event registration, [click here](#).

*This publication contains general information only and is based on the experiences and research of the author. The author is not, by means of this publication, rendering business, legal advice, or other professional advice or services. This publication is not a substitute for such legal advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified legal advisor. The author, his affiliates, and related entities shall not be responsible for any loss sustained by any person or entity that relies on this publication. The Author gives his permission to link, post, distribute, or reference this article for any lawful purpose, provided attribution is made to the author. The author can be reached at [tfox@tfoxlaw.com](mailto:tfox@tfoxlaw.com).*

© Thomas R. Fox, 2012